PTC Therapeutics, Inc. (PTCT) shareholders
Close on Nov 16, 2026Market cap $5.09BP/E –Yield –
Ownership
Institutional holdings as of Jun 30, 2026, from 13F filings
Shares held by institutions
Holders of more than 5%
Latest Schedule 13D (active) or 13G (passive) filed by each holder
| Holder | Shares | % of class | Filing | As of |
|---|---|---|---|---|
| BlackRock, Inc. | 11,904,696 | 14.80% | 13G (passive) amendment | Nov 30, 2025 |
| RTW Investments, LP Joint filing with Roderick Wong, M.D (9.80%) | 7,423,970 | 9.80% | 13G (passive) amendment | Dec 31, 2023 |
| Janus Henderson Group PLC | 7,193,433 | 8.70% | 13G (passive) amendment | Mar 31, 2026 |
| State Street Corporation | 5,512,555 | 6.60% | 13G (passive) | Sep 30, 2026 |
| Vanguard Portfolio Management | 4,871,329 | 5.88% | 13G (passive) | Mar 31, 2026 |
| Wellington Management Company LLP Joint filing with Wellington Management Group LLP (6.20%), Wellington Group Holdings LLP (6.20%) and 1 more | 4,787,123 | 6.10% | 13G (passive) amendment | Dec 31, 2024 |
| Steven Boyd Joint filing with Armistice Capital, LLC (5.96%) | 4,735,464 | 5.96% | 13G (passive) amendment | Jun 30, 2025 |
| Vanguard Capital Management | 4,284,448 | 5.17% | 13G (passive) | Mar 31, 2026 |
Top institutional holders
13F holdings as of Jun 30, 2026
| Holder | Shares | % of PTCT | Value | Change | % of portfolio |
|---|---|---|---|---|---|
| BlackRock, Inc. | 13,964,554 | 16.72% | $1.14B | +1,015,837 | 0.02% |
| Rtw Investments, LP | 7,746,415 | 9.27% | $631.88M | – | 5.39% |
| Jupiter Topco LLC | 7,236,402 | 8.66% | $590.18M | New | 0.24% |
| Vanguard Portfolio Management LLC | 4,928,111 | 5.90% | $401.99M | +123,517 | 0.02% |
| State Street Corp | 4,598,952 | 5.50% | $375.14M | +252,433 | 0.01% |
| Wellington Management Group Llp | 4,128,273 | 4.94% | $336.74M | +185,663 | 0.06% |
| Vanguard Capital Management LLC | 3,739,127 | 4.48% | $305.00M | +62,871 | 0.01% |
| Geode Capital Management, LLC | 2,207,376 | 2.64% | $180.09M | −2,578 | 0.01% |
| Toronto Dominion Bank | 2,165,846 | 2.59% | $176.67M | −860,117 | 0.20% |
| Westfield Capital Management Co LP | 1,956,156 | 2.34% | $159.56M | New | 0.52% |
| Hood River Capital Management LLC | 1,738,613 | 2.08% | $141.82M | +74,054 | 1.03% |
| William Blair Investment Management, LLC | 1,722,688 | 2.06% | $140.52M | New | 0.42% |
| D. E. Shaw & Co., Inc. | 1,548,919 | 1.85% | $126.35M | −91,462 | 0.06% |
| Tang Capital Management LLC | 1,500,000 | 1.80% | $122.36M | – | 5.56% |
| Bank Of America Corp /De/ | 1,452,277 | 1.74% | $118.46M | −434,564 | 0.01% |
| Driehaus Capital Management LLC | 1,440,107 | 1.72% | $117.47M | +424,335 | 0.68% |
| FMR LLC | 1,398,261 | 1.67% | $114.06M | −130,101 | 0.00% |
| Jefferies Financial Group Inc. | 1,357,042 | 1.62% | $110.69M | +2,583 | 0.73% |
| Fuller & Thaler Asset Management, Inc. | 1,156,819 | 1.38% | $94.36M | New | 0.26% |
| Pictet Asset Management Holding SA | 1,147,844 | 1.37% | $93.63M | −35,876 | 0.09% |
Institutional buying and selling by quarter
Positions opened, added to, reduced and closed by 13F filers
| Quarter | Holders | Shares held | % of shares | New / added | Reduced / closed | Shares bought | Shares sold |
|---|---|---|---|---|---|---|---|
| Q2 2026 | 382 | 100M | 100.0% | 77 / 142 | 113 / 44 | 21M | 9M |
| Q1 2026 | 352 | 96M | 100.0% | 61 / 145 | 102 / 56 | 21M | 9M |
| Q4 2025 | 353 | 93M | 100.0% | 101 / 127 | 96 / 37 | 19M | 9M |
| Q3 2025 | 294 | 83M | 99.6% | 55 / 101 | 105 / 41 | 13M | 10M |
| Q2 2025 | 284 | 81M | 96.5% | 60 / 111 | 80 / 35 | 11M | 9M |
| Q1 2025 | 261 | 79M | 94.4% | 51 / 85 | 93 / 27 | 11M | 9M |
| Q4 2024 | 240 | 78M | 93.1% | 56 / 77 | 78 / 17 | 11M | 12M |
| Q3 2024 | 203 | 79M | 95.0% | 31 / 70 | 70 / 26 | 12M | 5M |
| Q2 2024 | 199 | 81M | 96.4% | 45 / 78 | 62 / 27 | 5M | 14M |
| Q1 2024 | 184 | 90M | 100.0% | 34 / 53 | 69 / 22 | 10M | 7M |
| Q4 2023 | 173 | 87M | 100.0% | 26 / 72 | 56 / 30 | 18M | 13M |
| Q3 2023 | 180 | 81M | 97.2% | 23 / 81 | 58 / 46 | 11M | 10M |
Top mutual fund and ETF holders
Latest monthly portfolio reports (Form N-PORT)
410 funds held PTCT in Q2 2026, 56% of their shares through ETFs. Each fund counts once per quarter, from its quarter-end report.
| Fund | Shares | % of PTCT | Value | % of fund | As of |
|---|---|---|---|---|---|
| iShares Core S&P Small-Cap ETF | 4,997,138 | 5.98% | $407.62M | 0.37% | Jun 30, 2026 |
| Vanguard Total Stock Market Index Fund | 2,635,817 | 3.15% | $215.00M | 0.01% | Jun 30, 2026 |
| Vanguard Health Care Fund | 2,310,268 | 2.77% | $157.12M | 0.41% | Jul 31, 2026 |
| iShares Russell 2000 ETF | 2,127,944 | 2.55% | $173.58M | 0.21% | Jun 30, 2026 |
| Vanguard Small-Cap Index Fund | 1,902,975 | 2.28% | $155.23M | 0.08% | Jun 30, 2026 |
| State Street(R) SPDR(R) S&P(R) Biotech ETF | 1,357,466 | 1.62% | $110.73M | 1.03% | Jun 30, 2026 |
| Vanguard Small-Cap Growth Index Fund | 1,096,792 | 1.31% | $89.47M | 0.19% | Jun 30, 2026 |
| Janus Henderson Global Life Sciences Fund | 995,577 | 1.19% | $81.21M | 1.40% | Jun 30, 2026 |
| Vanguard Extended Market Index Fund | 951,394 | 1.14% | $77.61M | 0.08% | Jun 30, 2026 |
| Fidelity Small Cap Index Fund | 905,253 | 1.08% | $61.57M | 0.18% | Jul 31, 2026 |
| Hood River Small-Cap Growth Fund | 832,255 | 1.00% | $67.89M | 1.02% | Jun 30, 2026 |
| Fullerthaler Behavioral Small-Cap Growth | 780,300 | 0.93% | $63.65M | 1.03% | Jun 30, 2026 |
| State Street(R) SPDR(R) Portfolio S&P 600(TM) Small Cap ETF | 762,247 | 0.91% | $62.18M | 0.37% | Jun 30, 2026 |
| iShares S&P Small-Cap 600 Growth ETF | 745,407 | 0.89% | $60.80M | 0.74% | Jun 30, 2026 |
| iShares Russell 2000 Growth ETF | 653,446 | 0.78% | $53.30M | 0.35% | Jun 30, 2026 |
Officers, directors and major owners
People who filed Forms 3, 4 or 5 in the last two years
| Name | Role | Shares owned | % of shares | Latest filing |
|---|---|---|---|---|
| Matthew B. Klein | CHIEF EXECUTIVE OFFICER, Director | 383,868 | 0.46% | Aug 6, 2026 |
| Mark Elliott Boulding | EXEC. VP AND CLO | 105,272 | 0.13% | Oct 13, 2026 |
| Pierre Gravier | CHIEF FINANCIAL OFFICER | 83,986 | 0.10% | Jul 16, 2026 |
| Neil Gregory Almstead | CHIEF TECHNICAL OPS OFFICER | 65,662 | 0.08% | Jul 13, 2026 |
| Christine Marie Utter | SVP, CHIEF ACCOUNTING OFFICER | 70,199 | 0.08% | Jun 22, 2026 |
| Eric Pauwels | CHIEF BUSINESS OFFICER | 90,977 | 0.11% | Jun 12, 2026 |
| Lee Scott Golden | EVP & CHIEF MEDICAL OFFICER | 79,115 | 0.09% | Apr 6, 2026 |
| Michael Schmertzler | Director | 1,454,860 | 1.74% | Oct 16, 2026 |
| Glenn Jr Md Steele Phd | Director | 22,500 | 0.03% | Oct 2, 2026 |
| Hege Elisabeth Sollie-Zetlmayer | Director | 46,526 | 0.06% | Jul 30, 2026 |
| Mary L. Smith | Director | 21,813 | 0.03% | Jul 13, 2026 |
| Jessica Caroline Chutter | Director | 7,333 | 0.01% | Mar 26, 2026 |
| Stephanie Okey | Director | 8,000 | 0.01% | Mar 12, 2026 |
| Jerome B. Zeldis | Director | 22,500 | 0.03% | Jan 6, 2026 |
| David P. Southwell | Director | 22,500 | 0.03% | Jan 6, 2026 |
| Emma Reeve | Director | 10,666 | 0.01% | Jan 6, 2026 |
| Alethia Young | Director | 21,067 | 0.03% | Jan 6, 2026 |
| Allan Steven Jacobson | Director | 21,451 | 0.03% | Jan 6, 2026 |
Insider trades
Common stock transactions reported on Form 4, newest first
| Insider | Date | Transaction | Shares | Price | Value | Shares after |
|---|---|---|---|---|---|---|
| Michael Schmertzler Director | Oct 14, 2026 | Sale(10b5-1 plan) | −382 | $60.14 | $22.97K | 1,291,594 |
| Michael Schmertzler Director | Oct 14, 2026 | Sale(10b5-1 plan) | −2,118 | $59.52 | $126.06K | 1,291,976 |
| Mark Elliott Boulding EXEC. VP AND CLO | Oct 9, 2026 | Sale(10b5-1 plan) | −192 | $64.26 | $12.34K | 105,272 |
| Mark Elliott Boulding EXEC. VP AND CLO | Oct 9, 2026 | Option exercise | +192 | $39.42 | $7.57K | 105,464 |
| Michael Schmertzler Director | Oct 7, 2026 | Sale(10b5-1 plan) | −53 | $63.95 | $3.39K | 1,294,094 |
| Michael Schmertzler Director | Oct 7, 2026 | Sale(10b5-1 plan) | −2,447 | $63.38 | $155.09K | 1,294,147 |
| Mark Elliott Boulding EXEC. VP AND CLO | Oct 6, 2026 | Sale(10b5-1 plan) | −435 | $64.16 | $27.91K | 105,272 |
| Mark Elliott Boulding EXEC. VP AND CLO | Oct 6, 2026 | Option exercise | +435 | $39.42 | $17.15K | 105,707 |
| Mark Elliott Boulding EXEC. VP AND CLO | Oct 5, 2026 | Sale(10b5-1 plan) | −1,638 | $64.03 | $104.88K | 105,272 |
| Mark Elliott Boulding EXEC. VP AND CLO | Oct 5, 2026 | Option exercise | +1,638 | $39.42 | $64.57K | 106,910 |
| Glenn Jr Md Steele Phd Director | Sep 30, 2026 | Sale(10b5-1 plan) | −12,000 | $65.16 | $781.92K | 22,500 |
| Glenn Jr Md Steele Phd Director | Sep 30, 2026 | Option exercise | +12,000 | $11.23 | $134.76K | 34,500 |
| Michael Schmertzler Director | Sep 17, 2026 | Sale(10b5-1 plan) | −9,624 | $67.83 | $652.80K | 1,296,970 |
| Michael Schmertzler Director | Sep 17, 2026 | Sale(10b5-1 plan) | −376 | $68.45 | $25.74K | 1,296,594 |
| Michael Schmertzler Director | Sep 16, 2026 | Sale(10b5-1 plan) | −7,006 | $67.35 | $471.85K | 1,306,594 |
| Michael Schmertzler Director | Sep 16, 2026 | Sale(10b5-1 plan) | −2,994 | $66.58 | $199.34K | 1,313,600 |
| Michael Schmertzler Director | Sep 10, 2026 | Sale(10b5-1 plan) | −10,000 | $67.34 | $673.40K | 1,316,594 |
| Michael Schmertzler Director | Sep 9, 2026 | Sale(10b5-1 plan) | −572 | $68.67 | $39.28K | 1,326,594 |
| Michael Schmertzler Director | Sep 9, 2026 | Sale(10b5-1 plan) | −9,428 | $67.79 | $639.12K | 1,327,166 |
| Michael Schmertzler Director | Aug 27, 2026 | Sale(10b5-1 plan) | −11,890 | $71.55 | $850.73K | 1,337,204 |
| Michael Schmertzler Director | Aug 27, 2026 | Sale(10b5-1 plan) | −610 | $72.22 | $44.05K | 1,336,594 |
| Michael Schmertzler Director | Aug 26, 2026 | Sale(10b5-1 plan) | −5,626 | $73.18 | $411.71K | 1,349,094 |
| Michael Schmertzler Director | Aug 26, 2026 | Sale(10b5-1 plan) | −6,874 | $72.74 | $500.01K | 1,354,720 |
| Michael Schmertzler Director | Aug 20, 2026 | Sale(10b5-1 plan) | −9,419 | $70.78 | $666.68K | 1,364,675 |
| Michael Schmertzler Director | Aug 20, 2026 | Sale(10b5-1 plan) | −2,390 | $71.88 | $171.79K | 1,362,285 |
| Michael Schmertzler Director | Aug 20, 2026 | Sale(10b5-1 plan) | −691 | $72.92 | $50.39K | 1,361,594 |
| Michael Schmertzler Director | Aug 19, 2026 | Sale(10b5-1 plan) | −7,165 | $73.67 | $527.85K | 1,374,094 |
| Michael Schmertzler Director | Aug 19, 2026 | Sale(10b5-1 plan) | −5,335 | $72.86 | $388.71K | 1,381,259 |
| Mark Elliott Boulding EXEC. VP AND CLO | Aug 17, 2026 | Sale(10b5-1 plan) | −1,844 | $72.39 | $133.49K | 106,241 |
| Mark Elliott Boulding EXEC. VP AND CLO | Aug 17, 2026 | Sale(10b5-1 plan) | −969 | $72.90 | $70.64K | 105,272 |
| Mark Elliott Boulding EXEC. VP AND CLO | Aug 17, 2026 | Option exercise | +2,813 | $25.69 | $72.27K | 108,085 |
| Matthew B. Klein CHIEF EXECUTIVE OFFICER, Director | Aug 4, 2026 | Sale(10b5-1 plan) | −10,292 | $68.57 | $705.72K | 383,868 |
| Hege Elisabeth Sollie-Zetlmayer Director | Jul 28, 2026 | Award | +4,000 | – | – | 50,526 |
| Hege Elisabeth Sollie-Zetlmayer Director | Jul 28, 2026 | Award | +2,000 | – | – | 52,526 |
| Pierre Gravier CHIEF FINANCIAL OFFICER | Jul 14, 2026 | Sale(10b5-1 plan) | −3,494 | $80.35 | $280.74K | 83,986 |
| Mary L. Smith Director | Jul 9, 2026 | Sale(10b5-1 plan) | −10,000 | $90.00 | $900.00K | 21,813 |
| Mary L. Smith Director | Jul 9, 2026 | Sale(10b5-1 plan) | −5,834 | $90.00 | $525.06K | 21,813 |
| Mary L. Smith Director | Jul 9, 2026 | Option exercise | +5,834 | $42.95 | $250.57K | 27,647 |
| Mary L. Smith Director | Jul 9, 2026 | Option exercise | +10,000 | $42.95 | $429.50K | 31,813 |
| Neil Gregory Almstead CHIEF TECHNICAL OPS OFFICER | Jul 9, 2026 | Option exercise | +2,464 | $46.54 | $114.67K | 62,763 |
| Neil Gregory Almstead CHIEF TECHNICAL OPS OFFICER | Jul 9, 2026 | Sale(10b5-1 plan) | −2,464 | $90.25 | $222.38K | 60,299 |
| Neil Gregory Almstead CHIEF TECHNICAL OPS OFFICER | Jul 7, 2026 | Option exercise | +24,613 | $39.42 | $970.24K | 84,912 |
| Neil Gregory Almstead CHIEF TECHNICAL OPS OFFICER | Jul 7, 2026 | Sale(10b5-1 plan) | −3,956 | $87.17 | $344.84K | 80,956 |
| Neil Gregory Almstead CHIEF TECHNICAL OPS OFFICER | Jul 7, 2026 | Sale(10b5-1 plan) | −11,369 | $89.03 | $1.01M | 69,587 |
| Neil Gregory Almstead CHIEF TECHNICAL OPS OFFICER | Jul 7, 2026 | Sale(10b5-1 plan) | −9,288 | $89.44 | $830.72K | 60,299 |
| Mark Elliott Boulding EXEC. VP AND CLO | Jul 6, 2026 | Sale(10b5-1 plan) | −645 | $85.84 | $55.37K | 106,017 |
| Mark Elliott Boulding EXEC. VP AND CLO | Jul 6, 2026 | Sale(10b5-1 plan) | −601 | $86.38 | $51.91K | 105,272 |
| Mark Elliott Boulding EXEC. VP AND CLO | Jul 6, 2026 | Option exercise | +2,813 | $46.54 | $130.92K | 108,085 |
| Mark Elliott Boulding EXEC. VP AND CLO | Jul 6, 2026 | Sale(10b5-1 plan) | −387 | $83.10 | $32.16K | 107,698 |
| Mark Elliott Boulding EXEC. VP AND CLO | Jul 6, 2026 | Sale(10b5-1 plan) | −1,036 | $84.41 | $87.45K | 106,662 |
| Mark Elliott Boulding EXEC. VP AND CLO | Jul 6, 2026 | Sale(10b5-1 plan) | −519 | $85.84 | $44.55K | 105,873 |
| Mark Elliott Boulding EXEC. VP AND CLO | Jul 6, 2026 | Sale(10b5-1 plan) | −745 | $86.38 | $64.35K | 105,272 |
| Mark Elliott Boulding EXEC. VP AND CLO | Jul 6, 2026 | Option exercise | +2,266 | $39.42 | $89.33K | 107,538 |
| Mark Elliott Boulding EXEC. VP AND CLO | Jul 6, 2026 | Sale(10b5-1 plan) | −313 | $83.10 | $26.01K | 107,225 |
| Mark Elliott Boulding EXEC. VP AND CLO | Jul 6, 2026 | Sale(10b5-1 plan) | −833 | $84.41 | $70.31K | 106,392 |
| Neil Gregory Almstead CHIEF TECHNICAL OPS OFFICER | Jul 6, 2026 | Sale(10b5-1 plan) | −10,090 | $86.32 | $870.97K | 60,299 |
| Neil Gregory Almstead CHIEF TECHNICAL OPS OFFICER | Jul 6, 2026 | Sale(10b5-1 plan) | −8,786 | $85.35 | $749.89K | 70,389 |
| Neil Gregory Almstead CHIEF TECHNICAL OPS OFFICER | Jul 6, 2026 | Option exercise | +18,876 | $38.10 | $719.18K | 79,175 |
| Neil Gregory Almstead CHIEF TECHNICAL OPS OFFICER | Jul 6, 2026 | Option exercise | +2,474 | $39.42 | $97.53K | 62,773 |
| Neil Gregory Almstead CHIEF TECHNICAL OPS OFFICER | Jul 6, 2026 | Sale(10b5-1 plan) | −2,474 | $87.03 | $215.31K | 60,299 |
Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.
Short interest
Shares sold short and not yet bought back, as of Oct 30, 2026 (FINRA, reported twice a month)
Shares sold short, last 12 months
Short sale volume counts trades marked short on any given day, including market-maker hedging, so it runs far higher than the share of PTC Therapeutics's stock actually held short. Settlement fails (shares not delivered on time) peaked at 688 shares on Sep 21, 2026 over the last 90 days.
Planned insider sales
Notices of proposed sale filed on Form 144 before shares are sold
| Seller | Filed | Shares | Market value | Planned sale | Acquired through |
|---|---|---|---|---|---|
| Mark Elliott Boulding Officer | Oct 9, 2026 | 192 | $12.34K | Oct 9, 2026 | Stock Option Exercise |
| Section Six Partners, L.P. Affiliate of Director | Oct 7, 2026 | 10,000 | $643.50K | Oct 7, 2026 | Automatic Conversion of Preferred Stock into Common Stock Upon IPO |
| Mark Elliott Boulding Officer | Oct 6, 2026 | 435 | $27.91K | Oct 6, 2026 | Stock Option Exercise |
| Mark Elliott Boulding Officer | Oct 5, 2026 | 1,638 | $104.88K | Oct 5, 2026 | Stock Option Exercise |
| Glenn Jr Md Steele Phd Director | Sep 30, 2026 | 12,000 | $781.92K | Sep 30, 2026 | Stock Option Exercise |
| Section Six Partners, L.P. Affiliate of Director | Sep 9, 2026 | 40,000 | $2.74M | Sep 9, 2026 | Automatic Conversion of Preferred Stock into Common Stock Upon IPO |
| Section Six Partners, L.P. Affiliate of Director | Aug 25, 2026 | 50,000 | $3.65M | Aug 19, 2026 | Automatic Conversion of Preferred Stock into Common Stock Upon IPO |
| Michael Schmertzler Director | Aug 19, 2026 | 50,000 | $3.65M | Aug 19, 2026 | Open Market |
| Mark Elliott Boulding Officer | Aug 17, 2026 | 2,813 | $201.69K | Aug 17, 2026 | Stock Option Exercise |
| Matthew B. Klein Officer, Director | Aug 4, 2026 | 10,292 | $705.75K | Aug 4, 2026 | Restricted Stock Vesting |
| Pierre Gravier Officer | Jul 14, 2026 | 3,494 | $280.73K | Jul 14, 2026 | Restricted Stock Vesting |
| Mary L. Smith Director | Jul 9, 2026 | 15,834 | $1.43M | Jul 9, 2026 | Stock Option Exercise |
| Neil Gregory Almstead Officer | Jul 9, 2026 | 2,464 | $222.37K | Jul 9, 2026 | Stock Option Exercise |
| Neil Gregory Almstead Officer | Jul 7, 2026 | 24,613 | $2.19M | Jul 7, 2026 | Stock Option Exercise |
| Mark Elliott Boulding Officer | Jul 6, 2026 | 5,079 | $427.32K | Jul 6, 2026 | Stock Option Exercise |
See a number that looks wrong?